Print Email

MASCC Antiemetic Guidelines©

MASCC/ESMO Antiemetic Guidelines

© MASCC™  All rights reserved worldwide.
Organizing and Overall Meeting Chairs:
Richard J. Gralla, MD, Fausto Roila, MD, Maurizio Tonato, MD, Jørn Herstedt, MD

Roila F, Herrstedt J, Aapro M, et al; for the ESMO/MASCC Guidelines Working Group.
alt Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
Ann Oncol. 2010;21(suppl 5):v232-43.

Antiemetic Publications
Antiemetic Guidelines 2010 of the MASCC Antiemetic Study Group. 
Courtesy of MASCC and Springer, the updated full text version of the MASCC/ESMO Antiemetic Guideline papers found in Supportive Care in Cancer, vol. 19, Supplement 1/March 2011. >>View Articles

The papers in this supplemental issue of Supportive Care in Cancer represent a detailed summary of the deliberations from the consensus guideline meeting that took place in Perugia, Italy, in June 2009. Please refer to the PowerPoint guideline presentation for the most recent and updated version of the MASCC/ESMO Antiemetic Guideline.

MASCC Endorsed Guideline Partnerships

Acute AINV Guideline
From the Pediatric Oncology Group of Ontario (POGO) 
Guideline for the Prevention of Acute Nausea and Vomiting due to Antineoplastic Medication in Pediatric Cancer Patients
The purpose of this guideline is to provide healthcare practitioners with an approach to the prevention of acute antineoplastic-induced nausea and vomiting (AINV) in children receiving antineoplastic medication. The scope is limited to the prevention of AINV in the acute phase (within 24 hours of administration of an antineoplastic agent).

 For Questions or additional information, contact Executive Director, Åge Schultz,

icon Download the Guidelines:
For translation information please contact Anne Young at 

English - Updated January 2013
MASCC Guidelines-English (alt PDF 430KB) 
MASCC Guidelines-English (PPT 504KB) 


Arabic Translation - translated June 2010
Translated by Bassam Estfan
MASCC Guidelines-Arabic  
(alt PDF 236 KB)

Chinese Translation translated  April 2011
Translation provided by Shiyong Wang.
MASCC Guidelines-Chinese  (alt PDF 2.8MB) 
MASCC Guidelines-Chinese (PPT 651KB)

German Translation - translated  January 2014
Translation provided by ASORS.
MASCC Guidelines-German  (alt PDF 1.1MB) 
MASCC Guidelines-German (PPT 620KB)

Greek Translation - translated  November 2010
Translated by Ourania Nicolatou-Galitis and Erofili Papadopoulou
(alt PDF 1.2MB) 
(PPS 712 KB)

Portuguese Translation - translated March 2011
MASCC_Guidelines-Portuguese - PDF (alt PDF 1.2 MB)
MASCC_Guidelines-Portuguese - PPT (PPT 780 KB)

Russian Translation - translated  August 2011
Translated by Anton Snegovoy
(alt PDF 1.2 MB) 
(PPT 828 KB)

Serbian Translation - translated  April 2013
Translated by Snezana Bosnjak, Jelena Dimitrijevic and Ana Vujovic
(alt PDF 1.2 MB) 
(PPT 780 KB)

Spanish Translation - translated August 2011
Translated by Alvaro Menendez
(alt PDF 1.2 MB) 
(PPT 780 KB)

Turkish Translation - translated  August 2010
Translated by Ahmet Sezer, Ali Ayberk Besen, Huseyin Abali
(alt PDF 2.4 MB) 
(PPT 750 KB)

The following translations of the updated 2010 guidelines will be available soon. 

Italian Translation - translated December 7, 2005
Translated by Dr. Garassina
alt MASCC_Guidelines-Italian - PDF
MASCC_Guidelines-Italian - PPT

Japanese Translation - translated August, 2007
Thanks to Pfizer Japan for support of guideline translation.
alt MASCC_Guidelines-Japanese -PDF
MASCC_Guidelines-Japanese -PPT

Korean Translation - translated December, 2008
Thanks to Dr. Young Seon Hong for guideline translation.
alt MASCC Guidelines-Korean -PDF



powered by MemberClicks